Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
Advanced Science · 2026-06 · 13 (36)
DOI: 10.1002/advs.75837 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 28.05.2026. Verfasst von Feng Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China. Hauptthemen laut MEDLINE: Neoplasms, Nucleic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 285 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Despite significant advances in precision oncology, key oncoproteins such as Ras, MYC, and p53 remain historically difficult to drug. Conventional pharmacologic strategies are fundamentally constrained by their dependency on direct interactions with well‐defined structural domains, which these targets lack. Nucleic acid therapeutics offer a transformative paradigm to overcome this central limitation by redirecting pharmacological intervention to the mRNA and genomic levels, thereby operating independently of complex protein structures. In this review, we systematically examine the mechanisms of action and translational progress of diverse nucleic acid modalities, including ASOs, siRNAs, miRNAs, aptamers, and mRNA vaccines against these intractable targets. We comprehensively discuss their mechanisms, such as transcript degradation, translational inhibition, and upstream regulatory interference. Furthermore, we critically analyze the primary translational bottlenecks, specifically focusing on delivery efficiency, safety profiling, and scalable manufacturing, while highlighting recent advances in nanocarrier platforms. Finally, we explore future directions enabled by emerging technologies and computational design. Ultimately, this review highlights how nucleic acid therapeutics represent a paradigm shift, enabling precise regulation of “undruggable” cancer targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
- Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, P. R. China.
ORCID-Profile: Feng Xu
Förderung
- China Postdoctoral Science Foundation
Zitieren
APA
Xu, F., Wang, K., Lu, K., Hou, T., Chen, Y., Wang, X., & Jin, H. (2026). Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects. Advanced Science, 13(36). https://doi.org/10.1002/advs.75837
Vancouver
Xu F, Wang K, Lu K, Hou T, Chen Y, Wang X, et al. Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects. Advanced Science. 2026;13(36). doi:10.1002/advs.75837
BibTeX
@article{Xu2026,
author = {Xu, Feng and Wang, Ke and Lu, Kaizhong and Hou, Tianlun and Chen, Yuan and Wang, Xian and Jin, Hongchuan},
title = {Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {36},
doi = {10.1002/advs.75837}
}
EUVIMED